Resource Summary Report

Generated by dkNET on Sep 6, 2026

PE anti-human/mouse Granzyme B Recombinant

RRID:AB_2687031
Type: Antibody

Proper Citation

BioLegend Cat# 372207, RRID:AB_2687031

Antibody Information

URL: http://antibodyregistry.org/AB_2687031

Proper Citation: BioLegend Cat# 372207, RRID:AB_2687031

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: PE anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB_2687031

Vendor: BioLegend

Catalog Number: 372207

Alternative Catalog Numbers: 372208

Record Creation Time: 20231110T034045+0000

Record Last Update: 20260831T220639+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human/mouse Granzyme B Recombinant.

No alerts have been found for PE anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Zeng B, et al. (2026) HE4 drives PD-L1 expression in myeloid cells via IFN-?R-JAK-STAT3 signaling to promote tumor immune evasion. Cell reports. Medicine, 7(4), 102691.

Hu J, et al. (2026) Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell reports. Medicine, 7(6), 102833.

Roger A, et al. (2026) Sensory neuron production of substance P and TAFA4 promotes disease tolerance during viral infection. Immunity, 59(3), 682.

Pan D, et al. (2026) DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy. Cancer research, 86(12), 3026.

Kong L, et al. (2026) Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion. Cancer research, 86(6), 1480.

Yin Y, et al. (2025) Activated T cells degrade extracellular proteins to enhance effector functions. Cell reports, 45(1), 116797.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell reports. Medicine, 6(10), 102399.

Li G, et al. (2025) Microenvironmental ?-TrCP negates amino acid transport to trigger CD8+ T cell exhaustion in human non-small cell lung cancer. Cell reports, 44(1), 115128.

Wu ZY, et al. (2025) Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors. Cancer cell, 43(9), 1714.

Wu S, et al. (2025) Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy. Cell reports. Medicine, 6(3), 101984.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer cell, 43(1), 103.

Huang Y, et al. (2025) CD9 antibody enhances the anti-leukemia efficacy of ??T cells in adult B cell acute lymphoblastic leukemia. iScience, 28(11), 113752.

Huang SW, et al. (2025) Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases. eLife, 13.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. STAR protocols, 6(2), 103810.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Tu X, et al. (2024) S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. Journal of experimental & clinical cancer research : CR, 43(1), 72.

Yin S, et al. (2024) Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. Cell stem cell, 31(5), 717.

Shu G, et al. (2024) PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma. Cancer research, 84(10), 1659.

Si X, et al. (2024) Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell metabolism, 36(1), 176.

Wang C, et al. (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. Cell, 187(11), 2690.